62
Evaluation and Management of Hypertension Prof. Dr. S.C. Mandal Dr. Nagesh Waghmare (DM student) Cardiology, ICVS IPGME&R, Kolkata

Evaluation and management of hypertension

Embed Size (px)

Citation preview

Page 1: Evaluation and management of hypertension

Evaluation and Management of

Hypertension

Prof. Dr. S.C. Mandal

Dr. Nagesh Waghmare (DM student)

Cardiology, ICVS

IPGME&R, Kolkata

Page 2: Evaluation and management of hypertension

1. What is hypertension ?

2. Why should we treat it ?

3. Causes and mechanisms

4. Diagnosis and Initial evaluation

5. Treatment

6. Recent advances

Page 3: Evaluation and management of hypertension

What is hypertension ?

Page 4: Evaluation and management of hypertension

Hypertension paradox

• Can be easily diagnosed, but…

• Asymptomatic nature, delays diagnosis

• Advanced therapy available, but…

• Controlled in less than 1/3 rd of patients

Silent Killer

Page 5: Evaluation and management of hypertension

JNC 7 staging

Page 6: Evaluation and management of hypertension

Determinants

• Behavioral

– Nicotine

– Heavy drinkers

– Physical inactivity

– Diet low in fresh fruits and high in calories /

sodium.

• Genetic

Page 7: Evaluation and management of hypertension

Why should we treat it ?

• It affects 1 billion people worldwide

• India has become ―Capital of hypertension‖

• Burden is further rising

Page 8: Evaluation and management of hypertension

• In the ICMR study in 1994 demonstrated

25% and 29% prevalence of hypertension

among males and females respectively in urban

Delhi and 13% and 10% in rural Haryana.

Page 9: Evaluation and management of hypertension

• High BP causes

~ 54% of stroke

~ 47% of ischemic heart disease

• It also leads to

– Heart failure

– Peripheral vascular disease

– Renal failure

– Blindness due retinopathy, haemorrhages

Page 10: Evaluation and management of hypertension
Page 11: Evaluation and management of hypertension

Absolute benefits of treating hypertension

Page 12: Evaluation and management of hypertension

Impact of a 5 mmHg Reduction

Overall Reduction

Stroke 14%

Coronary Heart Disease 9%

All Cause Mortality 7%

Hypertension 2003;289:2560-2572.

Page 13: Evaluation and management of hypertension

So by controlling BP, we can

reduce deaths especially due to stroke

and MI.

Page 14: Evaluation and management of hypertension

Causes and mechanisms

Page 15: Evaluation and management of hypertension

• Primary hypertension

– In 90 – 95% of patients, a single reversible

cause cannot be identified

– Also called as Essential hypertension

• Secondary hypertension

– In 5 -10 % of patients

– May be curable

Page 16: Evaluation and management of hypertension

Primary hypertension

• It is divided in to 3 subtypes –

1. Systolic hypertension of young

• Between 17 -25 years of age

• Probably due to overactive sympathetic nervous

system

Page 17: Evaluation and management of hypertension

2. Diastolic hypertension in middle age

• Typically 30-50 years of age

• Elevated systemic vascular resistance

• Reduced ability to excrete sodium by kidney

Page 18: Evaluation and management of hypertension

3. Isolated systolic hypertension in older

adults

• After the age 55 years

• Most common form

• Due to age dependent stiffening of vessels

Page 19: Evaluation and management of hypertension
Page 20: Evaluation and management of hypertension

Mechanisms

• Neural

Sympathetic overactivity –

Deactivation of inhibitory neural inputs (e.g.

baroreceptors)

Activation of excitatory inputs (carotid body, renal

afferents)

• Vascular - endothelial cell dysfunction

• Hormonal - Renin- Angiotensin-

Aldosterone system

Page 21: Evaluation and management of hypertension
Page 22: Evaluation and management of hypertension
Page 23: Evaluation and management of hypertension
Page 24: Evaluation and management of hypertension

Diagnosis and Initial evaluation

Page 25: Evaluation and management of hypertension

Minimal laboratory testing required for the initial evaluation

• Blood electrolyte values,

• Fasting glucose concentration, and

• Serum creatinine level with calculated

glomerular filtration rate (GFR)

• Serum uric acid

Page 26: Evaluation and management of hypertension

• Fasting lipid panel

• Hematocrit

• Spot urinalysis, including urine albumin-to-

creatinine ratio

• Resting 12-lead electrocardiogram.

Page 27: Evaluation and management of hypertension

3 goals

• Initial evaluation should accomplish –

1. Accurate measurement of BP

2. Assessment of patients cardiovascular risk

3. Detection of secondary forms

Page 28: Evaluation and management of hypertension

Measurement of BP

• Office BP measurement

• Self monitoring at home

• Ambulatory monitoring

Page 29: Evaluation and management of hypertension

BP Measurement Techniques

Method Brief Description

In-office

• Two readings, 5 minutes apart

• Sitting in chair, not on exam table

• Confirm elevated reading in

contralateral arm

Self-

measuremen

t

• Provides information on response to

therapy

• May help improve adherence to therapy

• Evaluate ―white-coat‖ HTN

Page 30: Evaluation and management of hypertension

BP Measurement Techniques

Method Brief Description

In-office

Two readings, 5 minutes apart. Sitting in chair, not on

exam table. Confirm elevated reading in contralateral

arm.

Self-measurement

Provides information on response to therapy. May help

improve adherence to therapy and evaluate ―white-coat‖

HTN.

Ambulatory BP

monitoring

Indicated for evaluation of ―white-coat‖

HTN.

Can be used to confirm self-

measurement when inconsistent with in-

office measurement.

Page 31: Evaluation and management of hypertension

Self-Measurement of BP

Improves awareness and adherence

Instruction on proper use and technique should be

provided

Home measurement devices should:

• Have an arm cuff

• Be checked in office regularly

Validated meters:

BMJ 2001;322:531-536.

omronhealthcare.com

Dableducational.com

Daily Logs

Page 32: Evaluation and management of hypertension

Self-Measurement of BP

Home measurements of >135/85 mmHg

(or 125/75 in diabetes or renal disease)

are considered hypertensive

At least 50% of measurements should

be at or below goal

Page 33: Evaluation and management of hypertension

• Ambulatory monitoring also useful for

diagnosis of

– Nocturnal hypertension

– Baro-reflex impairment

• Wrist monitors are inaccurate and thus not

recommended

Page 34: Evaluation and management of hypertension

Recommended normal values

Average daytime BP < 135 / 85 mm Hg

Night time BP <120 / 70

24-hour BP < 130 / 80

Page 35: Evaluation and management of hypertension
Page 36: Evaluation and management of hypertension

Assessment of patients cardiovascular risk

• High-risk patients now includes most

cardiology patients—

1. Established CAD, CAD risk equivalents,

2. Carotid artery disease,

3. Peripheral artery disease,

4. Abdominal aortic aneurysm,

5. Heart failure, or

6. High risk for CAD (10-year framingham risk

score of >10%

Page 37: Evaluation and management of hypertension

Subclinical Target Organ Damage

• Left ventricular hypertrophy

• Carotid wall thickening or plaque

• Low estimated glomerular filtration rate

=60 mL/min/1.73 m

• Microalbuminuria

• Ankle-brachial BP index <0.9

Page 38: Evaluation and management of hypertension

This left ventricle is very thickened (slightly over 2 cm in

thickness), but the rest of the heart is not greatly enlarged.

This is typical for hypertensive heart disease. The

hypertension creates a greater pressure load on the heart to

induce the hypertrophy.

Page 39: Evaluation and management of hypertension

Established Target Organ Damage

• CNS: ischemic stroke, cerebral hemorrhage, transient

ischemic attack

• Heart disease: MI, angina, coronary

revascularization, heart failure

• Renal disease: diabetic nephropathy, renal impairment

• Peripheral arterial disease

• Advanced retinopathy: hemorrhages or

exudates, papilledema

Page 40: Evaluation and management of hypertension

Identifiable (secondary) forms of hypertension

• Renal disease is the most common cause (2-5%)

• Endocrine diseases

– Phaeochomocytoma

– Cusings syndrome

– Conn’s syndrome

– Acromegaly and hypothyroidism

• Coarctation of the aorta

• Iatrogenic

– Hormonal / oral contraceptive

– NSAIDs

Page 41: Evaluation and management of hypertension

Clinical clues for Renovascular HT

• Onset before 30 years or after 50 years

• Abrupt onset

• Severe or resistant hypertension

• Symptoms of atherosclerotic disease

elsewhere

Page 42: Evaluation and management of hypertension

• Negative family history of hypertension

• Smoker

• Worsening renal function after renin-

angiotensin inhibition

• Recurrent ―flash‖ pulmonary edema

Page 43: Evaluation and management of hypertension

• Examination shows -

Abdominal bruits

Other bruits

Advanced fundal changes

Page 44: Evaluation and management of hypertension

Hypertensive crisis

• Hypertensive emergencies –

– Malignant hypertension

– Accelerated hypertension

• Hypertensive urgencies

Page 45: Evaluation and management of hypertension

Treatment

Page 46: Evaluation and management of hypertension

"The Goal is to Get to Goal!”

Hypertension-PLUS-

Diabetes or Renal Disease

< 140/90 mmHg < 130/80 mmHg

Measurements and goals

should be provided to the

patient verbally and in writing

at each office visit

Page 47: Evaluation and management of hypertension

Treatment Overview

• Lifestyle modification

Same as for prevention

• Pharmacologic treatment

Initial therapy

Combination therapy

• What to do when a patient is still not at goal?

• Follow-up and monitoring

Page 48: Evaluation and management of hypertension

Lifestyle Modification

ModificationApproximate SBP

Reduction (range)

Weight reduction 5-20 mmHg/ 10 kg weight loss

Adopt DASH eating

plan8-14 mmHg

Dietary sodium

reduction2-8 mmHg

Physical activity 4-9 mmHg

Moderation of alcohol

consumption2-4 mmHg

JNC 7 Express. JAMA. 2003 Sep 10; 290(10):1314

Page 49: Evaluation and management of hypertension

DASH Eating Plan

• Low in saturated fat, cholesterol, and total fat

• Emphasizes fruits, vegetables, and low fat diary

products

• Reduced red meat, sweets, and sugar containing

beverages

• Rich in

magnesium, potassium, calcium, protein, and fiber

• 3 -1.5 g sodium per day

• Can reduce BP in 2 weeks

Sacks FM. NEJM. 2001; 344:3-10.

Page 50: Evaluation and management of hypertension

Pharmacological treatment

Page 51: Evaluation and management of hypertension

Algorithm for decision

Page 52: Evaluation and management of hypertension

Compelling indications

These are the associated comorbid

conditions, in which a particular

antihypertensive drug causes major

improvement outcome independent of BP

reduction

Page 53: Evaluation and management of hypertension

Condition Drug

Page 54: Evaluation and management of hypertension
Page 55: Evaluation and management of hypertension

Algorithm of therapy

Page 56: Evaluation and management of hypertension

When a Patient is Still Not at Goal?

• Optimize dosages or add additional drugs until

goal blood pressure is achieved

• What do you do when you are using several

effective medications?

– Consider causes of resistant hypertension

– Assure drug therapy is rational

– ―Tricks of the trade‖

Page 57: Evaluation and management of hypertension

Causes of inadequate response to therapy

• Pseudo-resistance

• Non-adherence to therapy

• Drug related causes

• Associated condotions

• Secondary hypertension

• Volume overload

Page 58: Evaluation and management of hypertension

How to improve maintenance of therapy ?

• Be aware of the problems leading to non-

compliance

• Articulate the goal of therapy - near-

normotension with few or no side effects.

• Educate the patient about the disease and its

treatment

Page 59: Evaluation and management of hypertension

• Maintain contact with patient

• Keep therapy inexpensive and simple

• Prescribe according to pharmacologic

principles

• Stop unsuccessful therapy and try different

drugs

Page 60: Evaluation and management of hypertension

• Anticipate and address side-effects

• Add effective and tolerated drugs stepwise

• Provide feedback and validation of success.

Page 61: Evaluation and management of hypertension

Recent advances

• Self – Management Support

• Renal sympathetic dennervation

• Baroreceptor stimulation

Page 62: Evaluation and management of hypertension

Thank you !